Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The closing price of Lineage Cell Therapeutics Inc (AMEX: LCTX) was $0.41 for the day, down -1.63% from the previous closing price of $0.42. In other words, the price has decreased by -$1.63 from its previous closing price. On the day, 1.21 million shares were traded. LCTX stock price reached its highest trading level at $0.439 during the session, while it also had its lowest trading level at $0.4092.
Ratios:
Our analysis of LCTX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.65 and its Current Ratio is at 3.65. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on August 20, 2024, initiated with a Buy rating and assigned the stock a target price of $4.
On November 02, 2022, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $5.
On June 14, 2022, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $4.B. Riley Securities initiated its Buy rating on June 14, 2022, with a $4 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 27 ’25 when BROADWOOD PARTNERS, L.P. bought 7,894,737 shares for $0.76 per share. The transaction valued at 6,000,000 led to the insider holds 49,560,992 shares of the business.
Howe Jill Ann bought 15,000 shares of LCTX for $8,850 on Nov 26 ’24. The Chief Financial Officer now owns 25,500 shares after completing the transaction at $0.59 per share. On Nov 26 ’24, another insider, Samuel George A. III, who serves as the General Counsel of the company, bought 15,000 shares for $0.60 each. As a result, the insider paid 9,000 and bolstered with 22,184 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LCTX now has a Market Capitalization of 95179040 and an Enterprise Value of 46966080. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.86 while its Price-to-Book (P/B) ratio in mrq is 1.15. Its current Enterprise Value per Revenue stands at 4.944 whereas that against EBITDA is -2.251.
Stock Price History:
The Beta on a monthly basis for LCTX is 1.43, which has changed by -0.6434783 over the last 52 weeks, in comparison to a change of 0.0635103 over the same period for the S&P500. Over the past 52 weeks, LCTX has reached a high of $1.40, while it has fallen to a 52-week low of $0.37. The 50-Day Moving Average of the stock is -23.43%, while the 200-Day Moving Average is calculated to be -43.85%.
Shares Statistics:
LCTX traded an average of 1.54M shares per day over the past three months and 1217750 shares per day over the past ten days. A total of 228.36M shares are outstanding, with a floating share count of 227.36M. Insiders hold about 0.44% of the company’s shares, while institutions hold 51.14% stake in the company. Shares short for LCTX as of 1743379200 were 26641663 with a Short Ratio of 17.31, compared to 1740700800 on 22027996. Therefore, it implies a Short% of Shares Outstanding of 26641663 and a Short% of Float of 18.490000000000002.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current assessment of Lineage Cell Therapeutics Inc (LCTX) involves the perspectives of 5.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.03, with high estimates of -$0.02 and low estimates of -$0.04.
Analysts are recommending an EPS of between -$0.09 and -$0.15 for the fiscal current year, implying an average EPS of -$0.12. EPS for the following year is -$0.09, with 5.0 analysts recommending between $0.01 and -$0.15.
Revenue Estimates
A total of 7 analysts have provided revenue estimates for LCTX’s current fiscal year. The highest revenue estimate was $30M, while the lowest revenue estimate was $3.34M, resulting in an average revenue estimate of $11.28M. In the same quarter a year ago, actual revenue was $9.5M
